Resmed (RSMDF) EBIT (2009 - 2026)

Resmed (RSMDF) has reported EBIT for 18 consecutive years, with $448.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT fell 1.28% year-over-year to $448.7 million; the trailing twelve-month figure through Jun 2026 stood at $1.9 billion (up 11.95% YoY), and the FY2026 full-year result was $1.9 billion, up 11.95% from the prior year.
• EBIT declined to $448.7 million in Q2 2026 per RSMDF's latest filing, from $499.8 million in the prior quarter.
• Across five years, EBIT topped out at $499.8 million in Q1 2026 and bottomed at $234.3 million in Q1 2022.
• Historically, EBIT has averaged $361.9 million across 5 years, with a median of $377.9 million in 2024.
• The sharpest annual moves came in 2023 and 2024: EBIT declined 1.82% in 2023, then surged 51.67% in 2024.
• Over 5 years, EBIT stood at $280.2 million in 2022, then declined by 1.82% to $275.1 million in 2023, then soared by 51.67% to $417.2 million in 2024, then climbed by 17.84% to $491.7 million in 2025, then decreased by 8.74% to $448.7 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered $448.7 million, $499.8 million, and $491.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.